ClinicalTrials.gg
RecruitingNCT06715215Updated Dec 4, 2024

Role of Acute Phase Proteins In Diagnosis of Immune Thrombocytopenia

An interventional study of Acute phase proteins in Immune Thrombocytopenia, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 1 Year to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Sohag University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
1 Year to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University — 6 open to participants now, 6 under way, none of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Sohag University.

Started
2024
the only one that year
No phase
5 of 11
2 open now
Registered
6th of 11
by date

Among the 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University, this one is the only one that started in 2024, is one of 5 with no phase, and was the 6th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

6 of the 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 1 Year to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University, or all of them as a file.
02

Study summary

Immune thrombocytopenia (ITP) are antibody-mediated disorders in which platelets are destroyed mainly through activating immunoglobulin (IgG) Fc receptors on phagocytes in the spleen and liver, eventually resulting in thrombocytopenia Acute phase proteins (APP) are inflammation markers that exhibit significant changes in serum concentration during inflammation. These are also important mediators produced in the liver during acute and chronic inflammatory states. Acute phase reactants can be classified as positive or negative, depending on their serum concentrations during inflammation. Positive acute phase reactants are upregulated, and their concentrations increase during inflammation. Negative acute phase reactants are downregulated, and their concentrations decrease during inflammation. Positive acute phase proteins include procalcitonin, C-reactive protein, ferritin, fibrinogen, hepcidin, and serum amyloid A. Negative acute phase reactants include albumin, prealbumin, transferrin, retinol-binding protein, and antithrombin CRP is now well established as a major acute phase protein and is used in daily clinical practice as a sensitive biomarker for infection and inflammation, with its level increasing from \<0.05 to >500 mg/L after acute infections. CRP is produced by hepatocytes, in response to inflammatory cytokines such as interleukin (IL)-6 and IL-1, with serum concentrations rising to >5 mg/L after 6 hours and peaking after ∼48 hours. In healthy young adult volunteer blood donors, the median concentration of CRP was found to be ∼0.8 mg/L CRP levels are useful as a clinical diagnostic tool for infection, and it is a common knowledge that ITP is triggered by viral infection that precedes the clinical picture of ITP by a few days to a few weeks Procalcitonin (PCT) is used as a reliable inflammatory biomarker with high sensitivity and specificity ferritin was confirmed as an inflammation and infection biomarker in the diagnosis of viral and bacterial infections.

03

Conditions studied

  • Immune Thrombocytopenia
04

Who can participate

Ages eligible
1 Year to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with less than 100 × 109/L diagnosed as immune thrombocytopenia by bone marrow findings .

Age of patients : from 1 year to 50 years.

Exclusion criteria

Exclusion Criteria:

    • Other causes of thrombocytopenia as:

      • Hypersplenism.
      • Bone marrow diseases including : aplastic anemia, leukemia and myelodysplastic syndromes.
      • Cancer treatments like chemotherapy and radiation therapy.
      • Exposure to toxic chemicals as arsenic and benzene.
      • Medications to treat bacterial infections (antibiotics)and treat seizures or blood thinner heparin.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    age and sex matched thrombocytopenic patients other than ITP.

    Causes of decreased platelets count other than immune thrombocytopenia

    Diagnostic Test: Acute phase proteins

  • Active comparator
    acute ITP patients

    Patients diagnosed as acute thrombocytopenia

    Diagnostic Test: Acute phase proteins

  • Active comparator
    chronic ITP patients .

    Patients diagnosed as chronic thrombocytopenia

    Diagnostic Test: Acute phase proteins

Interventions

  • Diagnostic testAcute phase proteins

    Assessment of acute phase proteins levels in patients diagnosed with immune thrombocytopenia

06

What researchers measure

Primary outcomes

  1. Acute phase proteins

    By taking serum samples from pateints and measure acute phase proteins levels

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gruys E, Toussaint MJ, Niewold TA, Koopmans SJ. Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B. 2005 Nov;6(11):1045-56. doi: 10.1631/jzus.2005.B1045. PubMed 16252337 ↗
  • Zeller B, Rajantie J, Hedlund-Treutiger I, Tedgard U, Wesenberg F, Jonsson OG, Henter JI; NOPHO ITP. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr. 2005 Feb;94(2):178-84. doi: 10.1111/j.1651-2227.2005.tb01887.x. PubMed 15981751 ↗
  • Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011 Apr;11(4):264-74. doi: 10.1038/nri2956. PubMed 21436837 ↗
  • Sullivan PS, Hanson DL, Chu SY, Jones JL, Ciesielski CA. Surveillance for thrombocytopenia in persons infected with HIV: results from the multistate Adult and Adolescent Spectrum of Disease Project. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 1;14(4):374-9. doi: 10.1097/00042560-199704010-00011. Erratum In: J Acquir Immune Defic Syndr Hum Retrovirol 1997 May 1;15(1):94. PubMed 9111481 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Dec 2025, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2024
First posted
Dec 4, 2024
StartActual
Nov 15, 2024
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 30, 2026
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06715215
Lead sponsor
Sohag University
Responsible party
Rana Mohamed Abdelhameed (Resident of clinical pathology department, Sohag University) — Principal investigator
First posted
Dec 4, 2024
Start date
Nov 15, 2024
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Dec 4, 2024

Study contacts

Rana M Abd Elhameed, Resident
Contact
rana_mohamed_post@med.sohag.edu.eg
01070198923
Eman H Ali, Assistant Professor
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion